Sports apparel giant Under Armour (UAA) released its financial results for the fourth quarter of 2018 on Feb. 12, before the opening bell. For the reporting period, revenue inched up 2% to $1.4 billion, generating net income of $4 million or $0.01 a share. Adjusted net income was $42 million or $0.09 per share.
Under Armour stock climbed more than 5% in pre-market trade after earnings beat Street estimates.
Over the last few weeks, analysts have maintained their estimates for the sports apparel retailer, with revenues projected to gain modestly year-over-year to $1.38 billion. The company, which recorded nil profit in the prior-year quarter, was expected to earn $0.04 per share this time.
For the full year 2018, Under Armour recognized $204 million in pre-tax charges, including $50 million in the fourth quarter.
Of the above total, $151 million were in cash related charges and $53 million in non-cash related charges.
LOOKING TO FY 2019
Despite many investors hoping for an upgrade, Under Armour reiterated its previous 2019 guidance that it announced back in December 2018.
Revenue is expected to grow 3-4% on flat North America and weaker international businesses. Gross margin is estimated to improve 60-80 basis points from 2018 adjusted margin. Operating income is touted to be between $210 million and $230 million.
FOCUS ON COMPETITION
Last week, Skechers (SKX) reported double-digit growth in fourth-quarter earnings and revenues, helped by robust international operations. Dick’s Sporting Good (DKS) will post its latest quarterly results on March 12, while Nike (NKE) is scheduled to release its third-quarter numbers on March 21.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips
https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the
Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,
A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies